Last reviewed · How we verify

NCT05185154

Natural Course and Prognosis of Hospitalized Patients With Cirrhosis

Status unknown Last updated 11 January 2022
What this trial tests

trial in Liver Cirrhosis in 336 participants. Status unknown.

Timeline
1 November 2021
Primary endpoint
31 October 2023
31 October 2025

Quick facts

Lead sponsorKangbuk Samsung Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment336
Start date1 November 2021
Primary completion31 October 2023
Estimated completion31 October 2025
Sites4 locations across South Korea

Conditions studied

Sponsor

Kangbuk Samsung Hospital

Who can join

20 and older, any sex, with Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective study is to evaluate the natural course and prognosis of hospitalized patients with liver cirrhosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other Kangbuk Samsung Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05185154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing